Novo Nordisk: Buyback and Legal Offensive Propel Shares Above Key Moving Average
Published on 06/24/2026 at 10:25 | Redaktion boerse-global.de
Novo Nordisk’s stock has clawed its way back above a closely watched technical threshold, as the Danish drugmaker deploys a combination of financial firepower and legal muscle to defend its GLP-1 franchise. The shares recently closed at €41.56, pushing past the 200-day moving average of €41.05 — a level many analysts view as the dividing line between a sustained uptrend and prolonged weakness.
The recovery, which now stands at more than 37% from the March trough of €30.25, has been fueled by a series of corporate actions and regulatory victories. The Relative Strength Index has climbed to 69, approaching overbought territory, suggesting momentum remains strong even as the stock still trades roughly 32% below its 52-week high of €61.20.
Buyback Machine Humming
Central to the bullish narrative is the company’s aggressive share repurchase programme. Since February, Novo Nordisk has bought back 20.9 million of its B-shares at an average price of 266.09 Danish kroner each, for a total outlay of around 5.6 billion kroner. The group now holds 38.1 million treasury shares, representing nearly 1% of its share capital.
The overall repurchase authorisation is generous: up to 15 billion kroner over 12 months. The current tranche, which began on 6 May 2026, allows buybacks worth as much as 11.2 billion kroner through February 2027. With about 9.5 billion kroner still available, management has ample room to continue supporting the share price.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Global Legal Crackdown Pays Off
Alongside the buyback, Novo Nordisk is tightening the screws on unauthorised copycat drugs. The High Court in Pretoria this week ordered South African pharmacy group iDexis to stop making or promoting any semaglutide-based products — the active ingredient in blockbusters Ozempic and Wegovy.
The ruling is the latest in a broader legal campaign that has seen Novo Nordisk file more than 130 lawsuits across 40 U.S. states. By targeting international markets, the company is trying to blunt the impact of patent expirations and generic competition that have already begun to weigh on sales in some regions.
Foundation Funds Next-Generation Research
Separately, the controlling Novo Nordisk Foundation has launched a major research initiative dubbed “CardioMetabolic Bridge”. The programme will receive roughly €60 million over six years to develop new therapies for obesity, diabetes and cardiovascular disease. The first laboratory opens this month in London, with additional sites in Germany and Italy planned later.
The foundation’s investment underscores the group’s long-term commitment to its therapeutic core, even as near-term headwinds mount from patent losses and pipeline uncertainty.
Pipeline Countdown: CagriSema and Wegovy Pill
On the product front, all eyes are on CagriSema, a combination weight-loss drug for which Novo Nordisk submitted a U.S. marketing application in December 2025. The FDA is expected to rule in the fourth quarter of 2026, a decision that could define the company’s competitive position for years to come.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
In China, CEO Doustdar has said the company will seek approval for the oral version of Wegovy “very soon”. The timing is tight: the semaglutide patent expired in China in March 2026, though data protection runs until early 2027. Management expects generic competition in the Chinese market from the second quarter of 2027. In India, copycat products are already on pharmacy shelves.
Novo Nordisk is betting that its manufacturing scale will keep most rivals at bay, but Pfizer and China’s Innovent Biologics remain in the race. The FDA’s verdict on CagriSema this autumn will go a long way toward determining whether Novo Nordisk can defend its lead in the GLP-1 segment — or whether the buyback and legal wins are merely buying time.
Ad
Novo Nordisk Stock: New Analysis - 24 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
